Status:
COMPLETED
mRNA Expression in Lymphocytes of Glaucoma Patients
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
University of Bonn
Conditions:
Glaucoma
Healthy Subjects
Eligibility:
All Genders
18-85 years
Brief Summary
The aim of the study is to compare messenger ribonucleic acid (mRNA) expression of various genes in lymphocytes between glaucoma patients and sex and age-matched healthy subjects. A secondary objectiv...
Detailed Description
Glaucoma is a leading cause of blindness world-wide. Chronic primary open-angle glaucoma is the most common form among Caucasian patients. The glaucoma patients will be divided into four groups: (1) h...
Eligibility Criteria
Inclusion
- Glaucoma patients
- diagnosis of chronic glaucoma with typical glaucomatous disc and visual field damage
- a present or past diurnal tension curve with an average intraocular pressure above 21 mmHg without treatment HTG)
- a present or past diurnal tension curve with an average intraocular pressure below 21 mmHg without treatment (NTG)
- a present or past diurnal tension curve with an average intraocular pressure above 21 mmHg without treatment and signs of pseudoexfoliation in the anterior segment (PEX)
- a juvenile-onset open-angle glaucoma with a present or past diurnal tension curve with an average intraocular pressure above 21 mmHg without treatment (Juvenile Glaucoma)
- Healthy subjects
- no history of ocular disease
- no history of systemic disease
- no history of alcohol/drug abuse
- normal blood pressure (100-140 / 60-90 mmHg)
- best corrected visual acuity above 20/25 in both eyes
- no pathological findings upon a slit-lamp examination and indirect fundoscopy
- IOP \< 20 mmHg in both eyes
Exclusion
- Ametropia \> 3 dpt
- Iridocorneal angle extremely narrow with complete or partial closure as determined by gonioscopy
- Pigmentary dispersion
- any abnormality which in the physician's view would prevent reliable applanation tonometry
- History of chronic or recurrent severe inflammatory eye disease such as scleritis or uveitis
- History of ocular trauma or intraocular surgery within the past 6 months
- History of infection or inflammation within the past 3 months
- History of clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy or retinal detachment
- Need for any concomitant medications that may interfere with the evaluation of ocular blood flow
- significant history and/or active alcohol or drug abuse
Key Trial Info
Start Date :
January 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00327509
Start Date
January 1 2004
End Date
December 1 2007
Last Update
August 20 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel, Eye Clinic
Basel, Canton of Basel-City, Switzerland, 4031